NOVACYT |
Market Closed -
Other stock markets
|
Pre-market 01:44:52 am | |||
| 0.714 EUR | +13.33% |
|
0.718 | +0.56% |
| Apr. 11 | Yourgene CEO to become head of Novacyt after acquisition | AN |
| Apr. 11 | Novacyt: changes to the Board of Directors | CF |
| Sales 2021 | 95.78M 102M | Sales 2022 | 21.04M 22.45M | Capitalization | 76.79M 81.95M |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.6M | Net income 2022 | -25M -26.68M | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 107M | Net cash position 2022 | 86.29M 92.09M | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 day | +13.33% | ||
| 1 week | +21.02% | ||
| Current month | +38.10% | ||
| 1 month | +31.01% | ||
| 3 months | +14.79% | ||
| 6 months | +26.37% | ||
| Current year | +0.14% |
1 week
0.58
0.75
1 month
0.500.75
Current year
0.490.75
1 year
0.421.00
3 years
0.426.72
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
James McCarthy
CEO | Chief Executive Officer | 58 | 21-01-04 |
Steven Gibson
DFI | Director of Finance/CFO | 41 | 17-03-31 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Heath
BRD | Director/Board Member | 76 | 15-06-28 |
John Brown
BRD | Director/Board Member | 69 | 23-09-07 |
Lyn Rees
BRD | Director/Board Member | 51 | 23-09-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 0.714 | +13.33% | 933,634 |
| 24-04-16 | 0.63 | -4.69% | 394,152 |
| 24-04-15 | 0.661 | +11.47% | 281,783 |
| 24-04-12 | 0.593 | +1.02% | 102,461 |
| 24-04-11 | 0.587 | -2.81% | 97,416 |
Real-time Euronext Paris, April 17, 2024 at 11:35 am EDT
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
2024-04-24
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.14% | 47.24M | |
| -27.82% | 916M | |
| -22.12% | 125M | |
| +1.90% | 57.56M | |
| -2.40% | 51.27M |
- Stock Market
- Equities
- ALNOV Stock
